INT351604

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.02
First Reported 2011
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 1.78
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (TXK, EGFR) plasma membrane (TXK, EGFR) cytoplasm (TXK, EGFR)
DNA binding (TXK) extracellular space (EGFR) endosome (EGFR)
TXK (Homo sapiens)
EGFR (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Stomach Cancer 141 81.84 Quite High
Death 3 78.40 Quite High
Cancer 189 63.16 Quite High
Breast Cancer 84 24.48 Low Low
Adenocarcinoma 27 5.00 Very Low Very Low Very Low
Esophageal Cancer 9 5.00 Very Low Very Low Very Low
Disease 9 5.00 Very Low Very Low Very Low
Cleidocranial Dysplasia 6 5.00 Very Low Very Low Very Low
Recurrence 6 5.00 Very Low Very Low Very Low
Atrophic Gastritis 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Compared to trastuzumab, lapatinib is a small molecule tyrosine kinase inhibitor (TKI) that targets both HER2 and epidermal growth factor receptor (EGFR/HER1) and can be administered orally.
tyrosine kinase Positive_regulation (targets) of HER1
1) Confidence 0.02 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.59 Pain Relevance 0
Compared to trastuzumab, lapatinib is a small molecule tyrosine kinase inhibitor (TKI) that targets both HER2 and epidermal growth factor receptor (EGFR/HER1) and can be administered orally.
tyrosine kinase Positive_regulation (targets) of epidermal growth factor receptor
2) Confidence 0.02 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.59 Pain Relevance 0
Compared to trastuzumab, lapatinib is a small molecule tyrosine kinase inhibitor (TKI) that targets both HER2 and epidermal growth factor receptor (EGFR/HER1) and can be administered orally.
tyrosine kinase Positive_regulation (targets) of EGFR
3) Confidence 0.01 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.59 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox